Literature DB >> 11930092

Polyethylene glycol without electrolytes for children with constipation and encopresis.

Vera Loening-Baucke1.   

Abstract

BACKGROUND: Children with functional constipation and encopresis benefit from behavior modification and from long-term laxative medication. Polyethylene glycol without electrolytes has become the first option for many pediatric gastroenterologists.
METHODS: Twenty-eight children treated with polyethylene glycol without electrolytes were compared with 21 children treated with milk of magnesia to evaluate the efficiency, acceptability, side effects, and treatment dosage of polyethylene glycol in long-term treatment of functional constipation and encopresis. Children were rated as "doing well," "improved," or "not doing well," depending on resolution of constipation and encopresis.
RESULTS: At the 1-, 3-, 6-, and 12-month follow-ups, bowel movement frequency increased and soiling frequency decreased significantly in both groups. At the 1-month follow-up, children on polyethylene glycol were soiling more frequently (P < 0.01) and fewer were improved (P < 0.01). At the 3- and 6-month follow-ups, both groups had similarly improved. At the 12-month visit, 61% of children on polyethylene glycol and 67% of children on milk of magnesia were doing well. Children on polyethylene glycol soiled more frequently (P < 0.01). None refused polyethylene glycol, but 33% refused to take milk of magnesia. The mean initial treatment dosage of polyethylene glycol was 0.6 +/- 0.2 g/kg daily. Polyethylene glycol had no taste, and no loss of efficacy occurred. Polyethylene glycol did not cause clinically significant side effects.
CONCLUSIONS: Polyethylene glycol without electrolytes is an alternative for long-term management of children with constipation and encopresis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11930092     DOI: 10.1097/00005176-200204000-00011

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  23 in total

1.  Long-term safety of PEG 4000 in children with chronic functional constipation: A biochemical perspective.

Authors:  Sun Hwan Bae
Journal:  Korean J Pediatr       Date:  2010-07-31

2.  Contrast enema as a guide for senna-based laxatives in managing overflow retentive stool incontinence in pediatrics.

Authors:  Ahmed Bassiuony Radwan; Mohammed Soliman El-Debeiky; Sameh Abdel-Hay
Journal:  Pediatr Surg Int       Date:  2015-07-15       Impact factor: 1.827

3.  Constipation in children: novel insight into epidemiology, pathophysiology and management.

Authors:  Shaman Rajindrajith; Niranga Manjuri Devanarayana
Journal:  J Neurogastroenterol Motil       Date:  2011-01-26       Impact factor: 4.924

4.  Use of Powder PEG-3350 as a Sole Bowel Preparation: Clinical Case Series of 245 Patients.

Authors:  Manish Arora; Patrick I Okolo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-07

Review 5.  Coexistence of constipation and incontinence in children and adults.

Authors:  S Nurko; S M Scott
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-02       Impact factor: 3.043

6.  Medical treatment of constipation.

Authors:  Jonathan D Siegel; Jack A Di Palma
Journal:  Clin Colon Rectal Surg       Date:  2005-05

7.  Childhood constipation: evaluation and management.

Authors:  Dinesh S Pashankar
Journal:  Clin Colon Rectal Surg       Date:  2005-05

8.  Medical management of constipation.

Authors:  Meredith Portalatin; Nathaniel Winstead
Journal:  Clin Colon Rectal Surg       Date:  2012-03

9.  Polyethylene glycol 4000 treatment for children with constipation: A randomized comparative multicenter study.

Authors:  Yishi Wang; Baoxi Wang; Xun Jiang; Mizu Jiang; Chundi Xu; Caihong Shao; Liying Jia; Zhihua Huang; Xiaohua Xu; Hua Liu; Lei Shang
Journal:  Exp Ther Med       Date:  2012-02-17       Impact factor: 2.447

10.  PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial.

Authors:  W Voskuijl; F de Lorijn; W Verwijs; P Hogeman; J Heijmans; W Mäkel; J Taminiau; M Benninga
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.